Predicting the effectiveness of insulin pump therapy on glycemic control in clinical practice: A retrospective study of patients with type 1 diabetes from 10 outpatient diabetes clinics in Sweden over 5 years

Diabetes Technology and Therapeutics

Volumn 17, Issue 1, 2015, Pages 21-28

  Clements, Mark ^a,b   Matuleviciene, Viktorija ^c,d   Attvall, Stig ^d,e   Ekelund, Magnus ^f   Pivodic, Aldina ^g   Dahlqvist, Sofia ^c   Fahlén, Martin ^h   Haraldsson, Börje ^d   Lind, Marcus ^c,d  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UDDEVALLA HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f HELSINGBORG HOSPITAL   (Sweden)

^g Statistiska konsultgruppen   (Sweden)

^h Section of Hematology   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; SWEDEN; BLOOD; BODY MASS; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN INFUSION; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE FACILITIES; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SWEDEN; TREATMENT OUTCOME;

EID: 84920773910     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2014.0139     Document Type: Article

References (37)

1. Diabetes Control and Complications Trial Study Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
2. Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
3. Lind M, Bounias I, Olsson M, et al.: Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 2011;378:140-146.
4. Pickup JC, Renard E: Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008;31(Suppl 2):S140-S145.
5. Hanaire H, Lassmann-Vague V, Jeandidier N, et al.: Treatment of diabetes mellitus using an external insulin pump: the state of the art. Diabetes Metab 2008;34:401-423.
6. National Board of Health and Welfare: Nationella Riktlinjer för diabetesva°rden. 2010. www.socialstyrelsen.se/nationellariktlinjerfordiabetesvarden (accessed September 20, 2014).
7. Livingstone SJ, Looker HC, Hothersall EJ, et al.: Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 2012;9:e1001321.
8. Bryant W, Greenfield JR, Chisholm DJ, et al.: Diabetes guidelines: easier to preach than practice? Med J Aust 2006;185:305-309.
9. Wood JR, Miller KM, Maahs DM, et al.: Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 2013;36:2035-2037.
10. Misso ML, Egberts KJ, Page M, et al.: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010;(1):CD005103.
11. Carlsson BM, Attvall S, Clements M, et al.: Insulin pumplong-term effects on glycemic control: an observational study at 10 diabetes clinics in Sweden. Diabetes Technol Ther 2013;15:302-307.
12. Pickup JC, Kidd J, Burmiston S, et al.: Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev 2006;22:232-237.
13. Pickup JC, Sutton AJ: Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections versus continuous subcutaneous insulin infusion. Diabet Med 2008;25:765-774.
14. Retnakaran R, Hochman J, DeVries JH, et al.: Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004;27: 2590-2596.
15. Anderson J, Attvall S, Sternemalm L, et al.: Effect of glycaemic control by short and long-term use of continuous glucose monitoring in clinical practice. J Diabetes Sci Technol 2011;5:1472-1479.
16. Carlsson B-M, Nord Andersson P, Almervik J, et al.: Availability of insulin pump therapy in clinical practice. Diabet Med 2012;29:1055-1059.
17. Lind M, Fahlén M, Eliasson B, et al.: The relationship between the exposure time of insulin glargine and risk of cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes 2012;6:53-59.
18. Lind M, Fahlén M, Odén A, et al.: The effect of insulin lispro on glycemic control in a large patient cohort. Diabetes Technol Ther 2009;11:51-56.
19. Lind M, Odén A, Fahlén M, et al.: The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables. PLoS One 2009;4:e4412.
20. Hoelzel W, Weykamp C, Jeppsson JO, et al.: IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166-174.
21. Bruttomesso D, Pianta A, Crazzolara D, et al.: Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet Med 2002; 19:628-634.
22. Olsovský J, Beránek M: The influence of long-term therapy with the insulin pump (CSII) in patients with type 1 diabetes mellitus on metabolic compensation and on the incidence of hypoglycaemia. Comparison with intensified conventional insulin therapy (MDI). Vnitr Lek 2007;53: 637-645.
23. Garmo A, Garmo H, Ä rnlöv J, et al.: Long-term treatment effects of insulin pump therapy. Pract Diab Int 2011;28: 295-299.
24. Lind M: Glycaemic control: evaluation of HbA1c as a risk factor and the effect of modern insulins in clinical practice. http://hdl.handle.net/2077/19641 (accessed September 20, 2014).
25. Hanas R: Psychological impact of changing the scale of reported HbA1c results affects metabolic control. Diabetes Care 2002;25:2110-2111.
26. Nicolucci A, Maione A, Franciosi M, et al.: Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 2008;25: 213-220.
27. Linkeschova R, Raoul M, Bott U, et al.: Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002;19:746-751.
28. Alemzadeh R, Palma-Sisto P, Holzum M, et al.: Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus. Diabetes Technol Ther 2007;9:339-347.
29. Gimenez M, Lara M, Conget I: Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: a pilot study. Diabetes Technol Ther 2010;12:517-521.
30. Pickup JC, Kidd J, Burmiston S, et al.: Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia prone type 1 diabetes: implications for NICE guidelines. Pract Diabet Int 2005;22:10-14.
31. Pickup JC, Freeman SC, Sutton AJ: Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011;343:d3805.
32. Miller KM, Beck RW, Bergenstal RM, et al.: Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1C levels in T1D Exchange Clinic Registry participants. Diabetes Care 2013;36: 2009-2014.
33. Patton SR, Clements MA, Fridlington A, et al.: Frequency of mealtime insulin bolus as a proxy measure of adherence for children and youths with type 1 diabetes mellitus. Diabetes Technol Ther 2013;15:124-128.
34. Workgroup on Hypoglycemia, American Diabetes Association: Hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249.
35. Bergenstal RM, Tamborlane WV, Ahmann A, et al.: Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-320.
36. Maahs DM, Caramori L, Cherney DZ, et al.: Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep 2013;13:550-559.
37. Bjornstad P, Cherney D, Maahs DM: Early diabetic nephropathy in type 1 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes 2014;21:279-286.